to identify microcephaly cases and conducted a nested case-control study to determine risk factors for microcephaly. Gestational age at birth was estimated based on antenatal ultrasound scanning ('Scanned cohort') or last menstrual period ('LMP cohort', including births ≥37 weeks' gestation only). Controls were newborns with head circumference Z scores between >-2 and ≤2 SD that were compared to microcephaly cases in relation to ZIKV exposure and other maternal and newborn factors.
(p=0.9). No samples had a ZIKV neutralising antibody titre that was at least fourfold higher than the corresponding dengue virus (DENV) titre. No ZIKV or other flavivirus RNA was detected in cord blood from cases or controls.
Microcephaly was prevalent in coastal Kenya, but does not Conclusions: appear to be related to ZIKV exposure; the ZIKV response observed in our study population was largely due to cross-reactive responses to DENV or other related flaviviruses. Further research into potential causes and the clinical consequences of microcephaly in this population is urgently needed. 
Keywords

Introduction
The recent Zika virus (ZIKV) epidemic in the Americas has focused attention on microcephaly as a major complication of in-utero infection and a cause of neurodisability in newborns 1 . Very little is known about the burden of microcephaly in Africa and, though ZIKV was first discovered in East Africa 2 and the Aedes mosquito vector for ZIKV is plentiful, it is not known whether ZIKV is a cause of microcephaly in the region. A cross-sectional survey in 1966-68 found high (52%) ZIKV antibody seroprevalence among children and adults in coastal Kenya 3 , though antibody cross-reactivity between ZIKV and other flaviviruses in circulation such as dengue virus (DENV) and West Nile virus (WNV) makes the interpretation of these data difficult. Several major flavivirus outbreaks have since occurred in the country [4] [5] [6] , with various serosurveys indicating ongoing flavivirus exposure 7, 8 . Notably, high flavivirus antibody seroprevalence was reported amongst pregnant women sampled in 2002-03 in coastal Kenya but the association with birth outcomes was not determined 9 .
We previously initiated a perinatal and maternal health research programme in coastal Kenya to identify risk factors for: 1) severe morbidity and mortality in mothers and newborns 10 and 2) preterm and small for gestational age (SGA) births in the INTERBIO-21 st Study 11 . As part of these two studies, we took head circumference measurements and demographic and anthropometric data allowing an estimation of: 1) the prevalence of microcephaly in coastal Kenya; 2) its association with maternal and newborn factors, and 3) its association with flavivirus exposure.
Methods
Study population and data collection
This was a population-based, observational, cohort study undertaken at Kilifi County Hospital (KCH) between January 2012 and October 2016. KCH is a rural public county hospital providing comprehensive obstetric care annually to approximately 5,000 women living along the Kenyan coast. All women completed a standardised admission record as part of two studies: an ongoing clinical surveillance study assessing risk factors for severe morbidity and mortality in mothers and newborns 10 and the st Study 11 . This included socio-demographic information, clinical history including antenatal clinic attendance, clinical findings on admission, delivery details, and maternal and newborn anthropometry. Gestational age was determined either by calculating the difference between the date of delivery and the date of the last reported menstrual period (LMP), including only births ≥37 weeks' gestation ("LMP cohort"); or by a pregnancy dating ultrasound scan done ≤24 weeks' gestation for a subset of participants enrolled in the INTERBIO-21   st   Study 11 , which included preterm and term births, referred to hereafter as the "scanned cohort".
All newborns had anthropometric measurements (i.e. head circumference, weight and length) taken within 48 hours of birth by nurses and fieldworkers trained as part of the INTERBIO-21 st Study, which included quarterly refresher training and continual quality control. Anthropometry for the scanned cohort was done in duplicate by two different fieldworkers, and discrepancies resolved by a third measurement.
11 Maternal blood for routine and research samples was collected on admission, and umbilical cord blood was collected at delivery. Maternal and cord blood samples were processed, and plasma stored at -80ºC, within 24 hours of collection. All mothers provided written informed consent for use of their biological samples and clinical data. The studies were approved by the Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (KEMRI SERU # 3296 and 1778).
Laboratory procedures Viral RNA detection. For qRT-PCR detection of ZIKV and other flaviviruses, viral RNA was isolated from cord plasma using the QIAamp® Viral RNA kit (Qiagen) according to manufacturer's instructions. Samples were then screened for ZIKV and other flavivirus RNA using the QuantiFast RT-PCR kit (Qiagen) and published pan-flavivirus (Flavi allS, Flavi all AS2, Flavi all AS4 and Flavi all probe 3 mix) 12 and ZIKV-specific primers and probes, Bonn E and Bonn NS1 13 , on an ABI 7500 Real Time PCR system. Sequences for all primers can be found in the indicated references. The PCR cycling conditions for the pan-flavivirus assay 12 were: 50°C for 20 minutes, 95°C for 15 minutes, followed by 45 cycles comprising 95°C for 15 seconds and 60°C for 1 minute. For ZIKV Bonn E and Bonn NS1
13 the conditions were: 50°C for 20 minutes, 95°C for 15 minutes, followed by 45 cycles comprising 95°C for 15 seconds and 58°C for 1 minute. A cycle threshold value of <40 was used to define positives for all three assays. RNA isolated from ZIKV MR766 strain and a range of other flaviviruses (DENV, WNV and Yellow Fever virus) cultured in Vero E6 cells were used as positive controls, and the PCR mastermix without template used as a negative control in these assays.
FRNT 90 assay. Cord plasma were screened for antibodies to ZIKV using a ZIKV focus reduction neutralisation test (FRNT 90 ) and an in-house IgM ELISA assay against ZIKV NS1 antigen strain MR766. For the FRNT 90 assay, heat-inactivated cord plasma samples were diluted to 1:20 in 100 µl Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal calf serum (D10), mixed with an equal volume of D10 containing approximately 100 focus-forming units of ZIKV MR766 strain, and incubated for 1 hour at 37ºC. The virus-plasma mixture was then overlaid onto 96-well flat-bottomed plates containing Vero E6 monolayers at 90% confluency for virus adsorption at 37ºC, 5% CO 2 for 24 hours. The virus-plasma mixture was aspirated from the wells, 100 µl of D10 was added and the plates incubated for a further 24 hours at 37ºC, 5% CO 2 . Immunostaining was then used to detect virus infection. Briefly, cells were gently washed with phosphate buffered saline (PBS), fixed in 4% paraformaldehyde in PBS for 10 minutes and permeabilized with permeabilization buffer (0.5% Triton X-100 in PBS) for 30 minutes. The plates were blocked in Blocker Casein (ThermoFisher) before addition of 0.5 µg/ml of the antiflavivirus E protein monoclonal antibody 4G2 (Native Antigen, UK, Cat. No AbFLAVENV-4G2) in permeabilization buffer for a 2-hour incubation at 37°C. Following a further series of washes, plates were incubated with a 1:1000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (Abcam, Cat. No. ab6789) in permeabilization buffer for 1 hour at 37°C, and colour development of foci done by addition of 3,3'-diaminobenzidine (Sigma) substrate for 10 minutes at room temperature. The plates were finally washed, air dried and foci counted using an AID ELISpot reader. Plasma samples that resulted in at least 90% reduction in foci relative to wells incubated with virus only were considered flavivirus seropositive. Antibody titres against the ZIKV MR766 strain, and against a local DENV-2 isolate obtained from a patient in coastal Kenya, were then estimated for seropositive samples using the FRNT 90 15 were used as positive controls, while plasma from two European individuals and a pool of cord plasma from 10 neonates without detectable responses to the ZIKV NS1 antigen were used as negative controls. IgM ratios, defined as the ratio between mean sample OD and the mean OD of the negative controls, were then obtained and seropositivity defined as an IgM ratio of >3 as done by others 16 .
Statistical analysis
Based on World Health Organization recommendations 14 , microcephaly (cases) was defined as a birth head circumference (HC) Z score < -3 SD from the mean for gestational age and sex using INTERGROWTH-21 st (IG21) newborn size reference charts for births <33 weeks' gestation 15 , and standards for births ≥33 weeks' gestation 16 . Controls were defined as newborns with HC Z scores between > -2 and ≤ 2 SD. Univariable logistic regression models were used to estimate associations between microcephaly and maternal or newborn variables hypothesised to be putative risk factors (22 variables tested; Table 1 ). A nominal two-sided p value was calculated as <0.002 (i.e. 0.05 divided by 22 for the number of covariates) following Table 1 . Association between maternal and newborn co-factors and microcephaly. The total number and prevalence of cases in the final case-control dataset, stratified by categories of neonatal and maternal variables, are shown. Data from the scanned and LMP cohorts are pooled in these analyses, but cohortspecific frequencies are shown in Table 3 . Crude odds ratios (OR), 95% confidence intervals (CI) and P values from univariable logistic regression models estimating associations with microcephaly with each variable in turn are shown. The reference population in each of the models is assigned a value of 1. The total number of newborns included in each analysis varies due to missing data for some variables. *Systolic or diastolic blood pressure >140 or >90 mmHg, respectively. There was an excess frequency of births with HC Z scores below -3 SD in the study population when compared to the expected normal distribution (Figure 2) . However, the observed frequency of births with HC Z scores between -3 and <-2 SD was similar to the expected normal distribution (Figure 2 ).
Covariate
Categories n/N cases (%) Crude OR (95% CI) P value
Newborn factors
A total of 16 (1.0%) of the 1529 newborns in the scanned cohort, and 198 (2.1%) of the 9532 newborns in the LMP cohort had a HC Z score <-3 SD. We hypothesised that the higher case prevalence in the LMP cohort was due to the known inaccuracy of LMP in estimating gestational age as compared to ultrasound scans, leading to preterm births being classified as term, in turn resulting in a lower Z score than would have been assigned had the gestational age been known accurately 14 . Indeed, among 1399 births (1253 term, 146 preterm) in the scanned cohort (used as gold standard) that also had corresponding LMP gestation ages, LMP gestation would have misclassified 9.3% (117/1253) of the term births as preterm births, and 39.7% (58/146) of preterms as term births. Therefore, to enhance the specificity of our case definition for associations, we excluded newborns with low birth weight (<2500 g, as per WHO guidelines) from the analysis of the LMP cohort. When this exclusion was applied the prevalence of microcephaly in the LMP cohort was 1.1% (95% CI 0.93, 1.39) among newborns weighing ≥2500 g (n=8333) and 8.6% (95% CI 7.13, 10.32) among those weighing <2500 g (n=1199), a difference that was statistically significant (χ 2 =286.05, p<0.001; Fig. 2 ). In contrast, low birth weight showed no association with microcephaly in the scanned cohort (χ 2 =0.40, p=0.5). All further analyses on the LMP cohort were therefore restricted to newborns weighing ≥2500 g at birth, which when pooled with the scanned cohort gave a case prevalence of 1.1% (95% CI 0.93, 1.35).
Associations between microcephaly and maternal and newborn factors To identify potential risk factors for microcephaly, we used a nested case-control approach whereby cases (n=111) were compared to controls (newborns with HC Z score > -2 and ≤ 2 SD, n=8986) with respect to various maternal and newborn variables by logistic regression (Table 1 and Table 3 ). A strong association was observed between microcephaly and being born small for gestational age (SGA), defined as birth weight <10 th centile for gestational age and sex on IG21 charts (OR=3.47, 95% CI 2.38, 5.07, p<0.001). Maternal nutritional status, anaemia, HIV status, parity, receipt of interventions provided in the antenatal clinic and all other newborn and maternal factors tested showed no significant association with microcephaly.
Associations between microcephaly and flavivirus exposure We used qRT-PCR and serological assays to investigate whether flavivirus exposure was associated with microcephaly in our dataset. To test for recent exposure to flavivirus, we measured IgM antibody responses against ZIKV NS1 antigen in cord plasma from 94 cases with available samples and 864 controls matched by year of birth. Overall IgM seropositivity against ZIKV NS1 was 2.4% (95% CI 1.60, 3.59), though this was strongly confounded by cross-reactive responses to DENV since sera from 25 patients from coastal Kenya with labconfirmed dengue infection 17, 18 were all seropositive on the ZIKV NS1 IgM assay. No association was evident between the ZIKV NS1 IgM response and microcephaly (Table 2) . Furthermore, no ZIKV or other flavivirus RNA could be detected in cord plasma from the 94 cases or from a random selection of controls (n=471).
Of the 94 cases with samples available, 71 had sufficient cord plasma material for ZIKV FRNT 90 assay. For the FRNT 90 assay, each of the 71 cases were matched to at least 10 controls by year of birth (n=755). The overall ZIKV FRNT 90 antibody prevalence in the study population was 8.2% (95% CI 6.54, 10.32), but this showed no association with microcephaly (Table 2 and Figure 3 ).
To characterise the ZIKV FRNT 90 response further we measured FRNT 90 antibody levels of the ZIKV FRNT 90 seropositive cord plasma (7 cases, 61 controls) against a local DENV-2 isolate and compared these to the corresponding ZIKV FRNT 90 titres. All ZIKV seropositive samples had antibody against DENV, with DENV FRNT 90 titres for most samples (43 of the 68 ZIKV seropositive samples) being at least fourfold higher than the corresponding ZIKV FRNT 90 titres (Figure 3) . No sample had a ZIKV FRNT 90 titre that was at least fourfold higher than that for DENV suggesting that the ZIKV response observed in our study population was largely due to cross-reactive responses to DENV or other related flaviviruses. Raw data used in these analyses are available as Underlying data
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Discussion
This study set out to estimate the prevalence of microcephaly in coastal Kenya in a cohort of babies born in a rural public county hospital using data from two prospective studies that estimated gestational age clinically and using ultrasound, respectively. We then sought to identify risk factors for microcephaly using a nested case-control design 10 . We found a prevalence of 1 to 2%, which given the 0.1% expected prevalence (<-3 SD in the reference populations) suggests a high, previously unrecognised, burden of microcephaly in this region. Using logistic regression we found that newborns with microcephaly were more likely to be born SGA. Finally, we did not detect any ZIKV or flavivirus RNA among cases or controls; nor differences in anti-ZIKV antibody responses between cases and controls.
A similarly high prevalence of microcephaly has been observed in Nigeria where approximately 1.9% of infants had a HC Z score <-3 SD 20 . In comparison, the average pre-ZIKV epidemic prevalence of microcephaly in 55 hospitals in the Americas was estimated at 0.04% (95% CI 0.041, 0.049) 21 , while the prevalence among 24 European Surveillance of Congenital Anomalies registries ranged between 0.004% and 0.04% 22 . During the ZIKV epidemic the overall microcephaly prevalence (HC Z score <-3 SD) in Pernambuco, one of the most severely affected states in Brazil, was estimated at 0.15% (95% CI 0.12, 0.17) 23 , almost ten times lower than that observed in our dataset.
Definitions of microcephaly are complex and confounded by prematurity. Could we have overestimated the prevalence? We showed that use of the LMP led to an overestimate of gestational age compared with the gold-standard method of ultrasound scans in early pregnancy, which may have led to an overestimate in the prevalence of microcephaly. Furthermore, errors in measuring head circumference could lead to misclassification. However, when we restricted analysis to the scanned cohort, in which gestational ages were calculated by high quality ultrasound scans in early pregnancy, and where two anthropometrists confirmed head circumferences, the prevalence of microcephaly remained high. Furthermore, even after restricting analysis in the LMP cohort to newborns with birth weight ≥2500 g, thus excluding all low birth weight (and hence most preterm births), the prevalence of microcephaly remained high.
We undertook detailed serological testing in cases and controls and did not find any ZIKV or flavivirus RNA. In addition, we showed no differences in anti-ZIKV FRNT 90 or IgM antibody response between cases and controls. Notably, all the ZIKV FRNT 90 seropositive samples were also seropositive for DENV. Comparison of FRNT 90 titres is conventionally used to infer specific flavivirus exposure 24 ; if the detected responses were due to recent ZIKV exposure we would expect ZIKV FRNT 90 titres to be at least fourfold higher than the DENV FRNT 90 titres in the corresponding sample(s) 24 . However, no sample had a ZIKV FRNT 90 titre that was fourfold higher than the corresponding DENV FRNT 90 titre. In fact, for more than half (63%) of the seropositive samples DENV FRNT 90 titres were at least fourfold higher than ZIKV FRNT 90 titres. Furthermore, the lack of seasonality in the risk of microcephaly, lack of trend by calendar year, and absence of any difference by urban/rural residence suggest it is unlikely that a vector borne or respiratory infection, including ZIKV, is the cause of microcephaly in our setting. The only strongly significant risk factor for microcephaly in our population was SGA; this sub-group accounted for 45% of all cases.
It is possible that we missed the viraemia in cord blood as a result of infection occurring earlier in pregnancy, as is common for ZIKV-associated microcephaly 1, 25 . Sample collection in this study was only done at the time of delivery 10 . However, if ZIKV was a significant cause of microcephaly we would expect an increase in IgM levels to ZIKV in cord blood, as reported elsewhere among children with microcephaly secondary to ZIKV [26] [27] [28] [29] . Furthermore, although molecular evidence of infection is not common among newborns with ZIKV-induced microcephaly, we would expect at least some to have prolonged ZIKV viraemia if this were a common cause. The complete absence of any molecular evidence of ZIKV in cases and controls, including in newborns with measurable cord blood anti-ZIKV FRNT 90 and IgM antibody responses, leads us to believe that the anti-ZIKV response detected in our study is cross-reactive to other flaviviruses. This hypothesis is supported by the high seroprevalence of DENV antibodies measured FRNT 90 in this study and by other methods in previous studies in coastal Kenya [7] [8] [9] 30 . Other potential infectious and non-infectious causes 31,32 , including genetic, nutritional and environmental factors, also warrant further investigation and may underlie the associations observed between microcephaly and SGA newborns (as observed by others 29 ).
In addition to using LMP in a subgroup to define gestational age, this study had other limitations. The study population only included births at KCH, and hence will have missed births occurring at home or in other local health facilities. However, we have important data from our uniquely detailed demographic surveillance system which indicates that approximately 40% of all births in the hospital catchment area occur at KCH.
This study has allowed the first estimation of the risk of congenital microcephaly in coastal Kenya. A 1-2% prevalence of microcephaly may impose a public health burden depending on the clinical outcomes associated. Future prospective studies to characterise and determine post-discharge mortality, neurocognitive outcomes and aetiology of microcephaly in the region are a priority. This project contains the following underlying data:
Data availability
• microcephaly_dataverse_v1 (dataset containing demographic information, anthropometric measures and results of lab assays for participants included in the study).
• GWarimwe_Microcephaly_Codebook (contains variable description and value labels). This project contains the following extended data:
Extended data
• GWarimwe_Microcephaly_missing_data_summary (summary of missing data for analysed variables).
• GWarimwe_Microcephaly_readme (readme file).
• microcephaly_dataverse_final (STATA analysis code used for data analysis presented in this article). The data used for this study were not specifically designed to answer these questions, but the authors try to address the data quality problems as well as possible.
The accuracy of classification of babies at birth as microcephalic or not depends on both accuracy of estimation of gestational age and of head circumference. The authors concentrate on the former source of inaccuracy, but it would be interesting to know also (if the data were recorded) the extent of discordant head circumferences in the smaller "scanned cohort" where duplicate measures were made. In addition, it would be informative to add a Figure showing the head circumferences and gestational ages of the cases <-3SD (classified as microcephaly) in the scanned cohort, shown against the Intergrowth chart.
In clinical practice, one would not expect a clinical diagnosis of microcephaly to be made without further neonatal measurements (including making sure any head molding at birth has resolved), so a degree of misclassification will inevitably remain, with a possible impact on the estimated prevalence, and diluting associations with risk factors.
The microcephaly prevalence (<3SD below the mean) is very high at 1% compared to other published estimates. Follow-up of these babies into childhood to measure their developmental outcomes, as well as brain imaging, is therefore important, as recommended by the authors.
It would be helpful if the authors could add some further details to the Methods and Results. Can the authors confirm that none of the microcephaly cases had other major malformations or syndromes? Is it possible that there was selective referral of high risk mothers to KCH? What evidence is there that congenital rubella or CMV might be causal factors in this population?
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In the manuscript "Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya" Barsosio and colleagues show their results of an extensive study on the potential role of congenital Zika virus (ZIKV) infections as a cause for microcephaly in Kenya. Although the number of microcephaly cases was high compared to other studies, ZIKV infections were not associated. The study provides very important information about the current role of ZIKV as a teratogenic agent in Africa, where the virus is widespread but reports about congenital malformations due to maternal ZIKV infections are scarce or absent. The size of the sample and the study design are a very good basis for well-founded scientific findings. There are some limitations regarding testing that should be addressed. In general, while Zika infection is not supported by the authors' results, it cannot be ruled out due to the diagnostic limitations inherent to endemic settings. This should be reflected in the text throughout.
ZIKV-specific IgM detection was done by an in-house IgM ELISA assay against the ZIKV NS1 antigen of the prototype strain MR766. It is hard to judge the diagnostic performance of this in-house assay in this particular population and thus the robustness of the authors' main laboratory findings. Those data must be provided in comparison to other assays. Notably, IgM detection for ZIKV diagnostics suffers from low sensitivity, particularly when targeting NS1-specific antibodies . Combining detection of IgM/IgA antibodies and of antibodies targeting the ZIKV envelope protein would likely increase sensitivity and thus strengthen the findings of the study.
The authors describe how ZIKV FRNT90 assays were conducted. The authors should add a technical description on how FRNT90 was done for dengue virus. In the same line of thought, choice of cell lines and virus stocks differing in the ratio of infectious to non-infectious particles (that still bind antibodies) can dramatically affect NT titers. Comparison of titers is thus always challenging in an endemic scenario in which people get infected multiple times with different flaviviruses. Because conserved epitopes among those multiple flaviviruses cross-stimulate anti-flaviviral immune responses and because different flaviviruses may elicit distinct antibody titer magnitudes, comparison of Zika and dengue NTs in this study deserves to be taken with caution. I agree that since dengue titers were consistently above Zika titers, the NTs are not supportive of Zika infection. I would be cautious though to state that they rule out the latter. In an endemic setting, a higher titer against dengue viruses, likely infecting a person multiple times due to the different co-circulating serotypes, does not rule out a Zika infection eliciting a relatively weaker titer. Solutions in patient diagnostics include testing of consecutive sera from acute and convalescence phases of infection, which is not feasible in this study. Can you compare titers in younger (likely less cumulative flavivirus infections) and older participants?
Only cord blood was tested. The authors should perform serologic testing of the mothers for ZIKV-specific IgG. Their-case control design should allow detecting potential ZIKV-specific differences in overall maternal exposure and height of ZIKV-specific neutralizing antibody titers as indirect evidence of potential congenital infection .
As discussed by the authors, the rate of microcephaly was exceptionally high in this study. 4.
linked to congenital malformations are readily available, including toxoplasmosis, syphilis, rubella virus or herpesviruses . Confirmation of another aetiology would strengthen the apparent lack of ZIKV.
Thomas Jaenisch
The manuscript provides useful and much needed data about the frequency of microcephaly in Africa, specifically in coastal Kenya, in the absence of ZIKV transmission. It would be great if the authors could provide even more detailed information about the distribution of head circumference in the cohorts they have followed. The manuscript should be edited before indexing:
Title:
The potential link to ZIKV infections or flavivirus exposure in the title is misleading, which should be clarified. The authors report that very likely there was no ZIKV transmission during the observation period. The current title leaves room for interpretation in the direction that the microcephaly observed in coastal Kenya is not associated to ZIKV infections, which were present in the region. The second weakness of the title is that the authors do not mention ZIKV infection directly in the title (even if ZIKV is the only flavivirus known to cause congenital abnormalities or microcephaly) because the serological results presented to not allow to make this statement.
Abstract -conclusions:
"Microcephaly was prevalent in coastal Kenya, but does not appear to be related to ZIKV exposure…" Same problem as above with the title. The authors continue in the next sentence with "… the ZIKV response observed in our study population was largely due to cross-reactive responses to DENV or other related flaviviruses". However, this still leaves room for interpretation. The most likely scenario here is that there was simply no ZIKV transmission during the observation period.
Methods -statistical analysis 5 line of statistical analysis: there seems to be a word missing "… using INTERGROWTH-21 (I21) newborn size-reference charts ….., and standards for birth…". Which standards?
The authors chose to compare microcephaly < 3SD (cases) with -2SD to +2SD (controls). Why did they not choose -1SD to +1SD, which would still have resulted in a big enough N for the controls? The reason for this question is that it currently is not clear how many 'controls' are close to -2SD (just above the cut-off) and could actually be counted as microcephaly or at least borderline according to some definitions. This reviewer thinks that this warrants a sensitivity analysis with the definition of -1SD -+1SD for controls.
Results and Figures
In Figure 1 , all study participants should be accounted for. However, we lack the number of the babies born with the head circumference between -3SD and -2SD (and potentially plus 3SD). Please include this in a footnote to the figure.
Figure 2 is important to understand the distribution of head circumference in the cohorts, and within different sub-populations. Please include the '-1 to +1' category. In addition, it would be interesting to include a histogram with the actual distribution of head circumference according to SD to really see the spread, and if the distribution approximates a normal distribution or not.
Discussion
The authors stratified the results according to the ascertainment of gestational age -'scanned' versus 'last menstrual period'. It is interesting to see the effect size of the potential biases resulting from the different methods and this reviewer would encourage the authors to extend the discussion around this 6 th st
